Imatinib in Systemic Sclerosis
NCT00506831
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
9
Enrollment
OTHER
Sponsor class
Conditions
Scleroderma, Systemic
Interventions
DRUG:
Imatinib mesylate
Sponsor
Stanford University